592208
SARS-CoV-2 Spike, Sotrovimab Biosimilar
Größe
£550.00
- SKU:
- 592208
- Reinheit:
- ≥95% (reducing SDS-PAGE, HPLC). Endotoxin: ≤1EU/mg (LAL)
- Lagerbedingungen:
- -20°C
- Hersteller:
- United States Biological
- Host:
- Human
- Immunogen:
- Recombinant protein corresponding to SARS-CoV-2 Spike RBD, expressed in CHO cells.
- Format:
- Supplied as a 0.2uM filtered solution, pH 7.4. No stabilizers or preservatives added.
- Weitere Details:
- Sotrovimab is an Fc-engineered human monoclonal antibody directed against the spike protein of SARS-CoV-2. Sotrovimab is a human monoclonal antibody (IgG1,k isotype). Sotrovimab biosimilar uses the same protein sequences as the therapeutic antibody sotrovimab. sotrovimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, sotrovimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. sotrovimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively. Applications: Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Sotrovimab. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
- Versandbedingungen:
- Blue Ice